Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$5.73 USD
-0.05 (-0.87%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.74 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Inozyme Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -71.17 | -67.06 | -56.62 | -56.42 | -19.72 |
Depreciation/Amortization & Depletion | -4.61 | -0.93 | 0.84 | 0.49 | 0.01 |
Net Change from Assets/Liabilities | -3.08 | 2.01 | 0.09 | -0.11 | 0.60 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.18 | 8.22 | 7.54 | 20.07 | 0.30 |
Net Cash From Operating Activities | -70.68 | -57.76 | -48.15 | -35.97 | -18.81 |
Property & Equipment | -0.30 | -0.41 | -0.40 | -0.57 | -0.14 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -53.35 | -4.99 | 43.19 | -116.61 | -8.25 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -53.65 | -5.40 | 42.80 | -117.18 | -8.39 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 85.97 | 68.74 | 0.61 | 149.81 | 22.97 |
Issuance (Repayment) of Debt | 40.00 | 4.05 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 125.97 | 72.79 | 0.61 | 149.81 | 22.97 |
Effect of Exchange Rate Changes | -0.02 | -0.03 | 0.02 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 1.63 | 9.60 | -4.72 | -3.34 | -4.23 |
Cash at Beginning of Period | 33.27 | 23.67 | 28.39 | 31.74 | 35.97 |
Cash at End of Period | 34.90 | 33.27 | 23.67 | 28.39 | 31.74 |
Diluted Net EPS | -1.37 | -1.78 | -2.40 | -5.11 | NA |
Fiscal Year End for Inozyme Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -50.38 | -23.35 | -71.17 | -49.63 | -32.99 |
Depreciation/Amortization & Depletion | -3.31 | -1.93 | -4.61 | -2.71 | -1.43 |
Net Change from Assets/Liabilities | 0.82 | -1.34 | -3.08 | -6.01 | -3.07 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.68 | 2.09 | 8.18 | 6.15 | 4.17 |
Net Cash From Operating Activities | -48.19 | -24.53 | -70.68 | -52.19 | -33.32 |
Property & Equipment | -0.03 | -0.03 | -0.30 | -0.19 | -0.19 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 28.24 | 10.43 | -53.35 | -46.98 | -2.38 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 28.21 | 10.39 | -53.65 | -47.18 | -2.56 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.62 | 0.16 | 85.97 | 85.95 | 16.24 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 40.00 | 27.50 | 27.50 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.62 | 0.16 | 125.97 | 113.45 | 43.74 |
Effect of Exchange Rate Changes | 0.01 | 0.01 | -0.02 | -0.15 | 0.03 |
Net Change In Cash & Equivalents | -19.36 | -13.97 | 1.63 | 13.94 | 7.89 |
Cash at Beginning of Period | 34.90 | 34.90 | 33.27 | 33.27 | 33.27 |
Cash at End of Period | 15.54 | 20.93 | 34.90 | 47.21 | 41.16 |
Diluted Net EPS | -0.44 | -0.38 | -0.33 | -0.29 | -0.35 |